Investment Objective

Index outperformance through fundamental deep-dive equity research and subsequent investment in quality companies with widening business moats and earnings power. Alpha generation through time-arbitrage by taking a private buyer approach to public companies, low portfolio turnover, and average portfolio concentration to minimize drawdown. No market timing to enable stable participation in broader market returns.

Month-to-Date March	2.34% (NAV: \$1,632.30)
Year to Date	8.02%
Last 3 months	8.02%
Last 12 months	24.23%
2023	20.05%

Monthly Commentary

As of March 28, 2024, the Net Asset Value (NAV) of the USD Institutional share class, net of fees, of the FAM US Long Only stood at USD 1,632.30. This represents an increase of 2.34% for the month.

During the month, the U.S. market continued positively on its upward trajectory, consolidating a strong performance for the first quarter of the year. Fundamentals across most sectors were resilient, enhanced by upbeat economic sentiment. Some earnings of large companies across regions were reported and exceeded expectations. The agenda of policy makers seems now readjusted to a less dovish one for the year, with fixed income markets now challenged by expectation of fewer and later interest rate cuts. The conflict between Russia and Ukraine continues, while tensions between Israel and Gaza are rather intensifying. Commodity prices overall increased, namely oil and its derivative products. Equity markets were positive, the S&P 500 TR Index gained 3.22%, while the MSCI ACWI Index was up 3.14%. Fixed income markets were slightly positive, with the Global Bond Aggregate TR Index up 0.91%. Volatility remained broadly unmuted over the month.

Last month's top contribution came from Novo Nordisk (+50bps for the portfolio). The company operates a strong pipeline with a broad product portfolio, steady increase in production capacity and solid operating profit growth. Our investment case lies on leadership in the obesity space, brand value and protein engineering capabilities of the name. We like the opportunities from the expansion into obesity treatments and oral diabetes drugs.

On the negative side, the main detractor from the performance of the portfolio was Zoetis (-17bps for the portfolio). The company is facing some headwinds from broader veterinary sector. Nevertheless, gains in pharma and diagnostics may continue despite depressed veterinary visits. Launch of Librela, a new pain relief medicine for dogs, is now a key catalyst for additional organic growth. We remain convinced of our investment case.

8.02%	Expected Dividend Yield p.a	1.09%
8.02%	Weighted Market Cap.	328.78 Bln
24.23%	Portfolio RoE	39.37%
20.05% 63.23%	P/E Weighted Avg.	23.1x
0.72	Gross Margin	44.7%
17.25%	Alpha (ITD Annual) to S&P 500	-0.87
-10.55%	Beta (ITD Annual) to S&P 500	0.93

Top Equity Holdings

Since Inception Sharpe Ratio Volatility Max Monthly Drawdown

Top Sectors

Novo Nordisk	6.4%	Information Technology	22.1%
Microsoft	5.4%	Financials	21.7%
Fiserv	4.3%	Health Care	17.9%
Motorola Solutions	4.2%	Consumer Discretionary	10.6%
Alphabet	4.0%	Industrials	7.3%

Monthly NAV Change in % (incl. Distributions)

NAV Returns	Jan	Feb	Mar	Apr	Мау	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2024	3.65%	1.82%	2.34%										8.02%
S&P 500 TR Index	1.68%	5.34%	3.22%										10.56%
2023	3.66%	-1.36%	2.09%	3.01%	-1.38%	3.23%	3.70%	-1.07%	-4.86%	-2.32%	9.57%	4.99%	20.05%
S&P 500 TR Index	6.28%	-2.44%	3.67%	1.56%	0.43%	6.61%	3.21%	-1.59%	-4.77%	-2.10%	9.13%	4.54%	26.29%
2022	-10.55%	-0.66%	4.06%	-7.87%	-3.66%	-6.45%	7.58%	-2.94%	-7.74%	5.41%	2.64%	-0.48%	-20.35%
S&P 500 TR Index	-5.17%	-2.99%	3.71%	-8.72%	0.18%	-8.25%	9.22%	-4.08%	-9.21%	8.10%	5.59%	-5.76%	-18.32%
2021	-0.35%	0.54%	2.17%	7.36%	-0.80%	2.42%	3.11%	3.25%	-3.40%	5.74%	0.64%	2.16%	24.84%
S&P 500 TR Index	-1.01%	2.76%	4.38%	5.34%	0.70%	2.33%	2.38%	3.04%	-4.65%	7.01%	-0.69%	4.75%	29.88%
2020	-	-	-	-	5.90%	-0.54%	7.12%	7.35%	-3.78%	-0.90%	7.49%	1.98%	26.60%
S&P 500 TR Index	-	-	-	-	4.76%	1.99%	5.64%	7.19%	-3.80%	-2.66%	10.95%	3.71%	32.84%

FOR QUALIFIED INVESTORS ONLY / FOR MARKETING PURPOSE ONLY

FAM US Long Only Fund Monthly Report March 28, 2024

Fund Facts

Fund Type UC
Fund Manager Fairway Asset Management
Fund Management Co. 1741 Fund Management
Custodian Liechtensteinische Landesbank
Representation Switzerland 1741 Fund Solutions
Paying Agent Tellco
Auditor Ernst & You
Trading Frequency Da
Redemption Notice No
Share Class A (Min. USD 50,000) AT0000A2EK
Share Class B (Inst. – Min. USD 500,000) AT0000A2EK
Fund Assets USD 4.0 M
Reference Currency U
Launch Date 04.05.20

Fee Structure	Institutional (capped at 100m)
Management Fee	Institutional 0.8%; Retail 1.0%
Hurdle Rate	S&P 500 Index

The information contained in this document should not be considered as an offer, or solicitation, to deal any of the investments or funds mentioned herein, by anyone in any jurisdiction in which the genom making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation. The fund is not registered in the United States of America or any of its states, territories, possessions or other areas subject to its jurisdiction or or the benefit of a United States person. Past performance or anchievements, or industry results, events of activity, performance or anchievements. Or industry results, which may be materially different from any future results, performance or achievements and unknown risks, uncertainties and other factors which may be distributed in symical departments. Such forward-looking statements do not guarantee any future results, levels of activity, performance or achievements, or industry results, and any direct actual graphics contained herein through copying or otherwise, or oudlying the same in any way without express prior written consent of FAM. The State of the orging of the Fund is Austria. This document may obly be distributed in Switzerland. The Baais documents of the fore solicitation and the past and for informational purposes and only to those, to whom it was distributed and may not use of well-informed, institutional, aseni-professional and qualified investors" and for informational purposes and only to those, to whom it was distributed and way not whote express prior written consol of AM. The Guaran the any individe the performance is and the particular, is document, in any jurisdiction and pathes considered and understand the potential information and materials and expressite and on any on that persons in atthe addite and the pathet a